# Clinical Study of U32 in Patients With Acute Myeloid Leukemia

> **NCT07036250** · PHASE1,PHASE2 · RECRUITING · sponsor: **Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd** · enrollment: 20 (estimated)

## Conditions studied

- Acute Myeloid Leukaemia

## Interventions

- **DRUG:** U32 CAR-T

## Key facts

- **NCT ID:** NCT07036250
- **Lead sponsor:** Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-07-03
- **Primary completion:** 2027-12-31
- **Final completion:** 2029-12-31
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2025-06-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07036250

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07036250, "Clinical Study of U32 in Patients With Acute Myeloid Leukemia". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT07036250. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*